As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that market experts ... little bit misplaced on the charts.” READ ALSO: 7 Best ...

Novo Nordisk's shares faced a significant decline due to competition and sales lag, prompting concerns about its market edge.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

BofA analyst Sachin Jain lowered the firm’s price target on Novo Nordisk (NVO) to DKK 910 from DKK 1,075 and keeps a Buy rating on the shares.

Danish biotech giant Novo Nordisk is trading at an extremely attractive valuation — particularly relative to its main rival, ...

Novo Nordisk (NVO) just agreed to shell out up to $2 billion for the global rights to a Chinese weight-loss drug—and the market wasn’t ...